Drupal.behaviors.print = function(context) {window.print();window.close();}>
FDA Highlights Use of Genomic Markers in Draft Guidance for Enrichment Strategies for Drug Trials
January 02, 2013
FDA Highlights Use of Genomic Markers in Draft Guidance for Enrichment Strategies for Drug Trials
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
AB Sciex API 3200MD and 3200MD QTRAP Mass Specs Receive EU CE-IVDD Mark
May 24, 2013 / ProteoMonitor
FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients
May 15, 2013 / GenomeWeb Daily News
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO
May 10, 2013 / ProteoMonitor
Data from Exact Sciences' Clinical Trial Sends Stock Plunging
April 18, 2013 / GenomeWeb Daily News